



Top Global CRO Advised by Almac's Clinical Supply Management Team

Almac's Clinical Supply Management team oversight helps a top global CRO client optimise the drug supply for a study sponsor based in Asia running 3 phase II studies in the EU, US and Asia.

Supply With Care™



Phase III



BACKGROUND

A top global Contract Research Organisation (CRO), approached Almac to provide Clinical Supply Management (CSM) which included forecasting and drug supply management for a small, pharmaceutical company based in Asia running three, phase II clinical trials.

All studies were double-blinded, placebo-controlled, metabolic studies to compare the efficacy of different doses of the sponsor's Investigational Medicinal Product (IMP) in different subject populations. All 3 studies were conducted within 8 countries located in the US, EU and Asia.

The studies each enrolled between 200-300 subjects at 40-100 sites, and had 4-8 treatment arms.

Almac generated the bulk drug and packaged supply requirement forecasts to enable the sponsor to plan their manufacturing schedules and Almac to plan their production and distribution needs. The Clinical Supply Manager (CSM) was also responsible for the Interactive Response Technology (IRT) set-up to ensure the medication management strategies were aligned with the packaging and distribution approaches.

The business challenges

Due to the sponsor's limited production capacity there was limited IMP available for study start-up. The IMP was a combination drug with device. The use of the device was unclear. Almac and our client had to seek further clarification around the mechanics of the device.


After initial quantities had been packaged and released and two of the three studies had commenced recruiting, an issue was identified with the second delivery of IMP resulting in additional inspections and a reduction in the available IMP for labelling and packaging. This meant the trial was at a high risk of having to stop as supply was unable to be released to meet patient demand.

The Almac solution

The Almac CSM reviewed the client's packaging designs in conjunction with the protocol and proposed a number of changes with the focus being on minimising the drug requirements.

The packaging designs were changed for 2 of the protocols. The number of different pack types were reduced, which streamlined the production operations and reduced costs. The new strategy enabled all packs to utilise the same cartons, inserts and label text. This led to some cost savings and a simplification in the IRT set-up. The changes also reduced the quantity of IMP required at site start-up by 25%.

Figure 1: Supply Chain Assessment (IMP Produced)



Clinical forecasting

The Almac CSM reviewed the study timelines, site activation schedules and predicted randomisations for each region for all 3 studies. Utilising Almac's clinical forecasting solution – SupplyWise™, the CSM proposed the optimum packaging quantities of each pack type per study as well as providing the sponsor and packaging facility with a forecast for the outstanding IMP delivery timing and quantities.


Change management

After initial quantities had been packaged and released and 2 of the 3 studies had commenced recruiting, an issue was identified with the second delivery of IMP. Almac's Qualified Person (QP) team worked continuously with the client for 3 weeks to resolve the issue.

The role of the CSM overseeing the study was critical as their knowledge of the packaging and distribution timelines enabled them to amend the proposed re-supply packaging quantities and prioritise the operations, to minimise the potential for drug shortages in the ongoing trials. Alongside the proactive CSM managing the study, Almac's global capacity and flexibility meant they were able to revise production schedules to meet the new timelines.

The results

- As a result of Almac's CSM oversight the CRO and sponsor were able to ensure study timelines were met and there were no drug shortages at any of the clinical sites.
- Re-design of the proposed patient packs by the Almac CSM resulted in a 25% decrease in the quantity of IMP to be manufactured for the 3 Phase II trials. This minimised drug wastage, saving the client money.



almacgroup.com

GET IN TOUCH

Global HQ
+44 28 3836 2436

EU HQ
+353 42 932 0718

US HQ
+1 215 660 8500

Souderton PA USA
+1 (215) 660-8520

Asia HQ
+65 6309 0720

Japan
+81 3 4233 9178

clinicalservices@almacgroup.com

Supply With Care™

© Almac Group Ltd. All rights reserved AM1717